A mid-stage anticancer MET inhibitor drug. The compound is a phase 2 small molecule inhibitor of the cell surface enzyme which stimulates cancer cell scattering, invasion and protection from apoptosis. It is being developed to treat gastric and esophageal cancers.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Amgen (AMG 337)‘s full profile, request access.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Amgen (AMG 337)‘s full profile, request access.
Request a free trial